Ludwig, H., & Goldschmidt, H. (2017). Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: Results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and lymphoma, 58(10), . https://doi.org/10.1080/10428194.2017.1298755
Chicago-Zitierstil (17. Ausg.)Ludwig, Heinz, und Hartmut Goldschmidt. "Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup." Leukemia and Lymphoma 58, no. 10 (2017). https://doi.org/10.1080/10428194.2017.1298755.
MLA-Zitierstil (9. Ausg.)Ludwig, Heinz, und Hartmut Goldschmidt. "Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup." Leukemia and Lymphoma, vol. 58, no. 10, 2017, https://doi.org/10.1080/10428194.2017.1298755.